Yusheng Han purchased 31,487 ADSs of Burning Rock Biotech, totaling 72,733 ADSs purchased, signaling confidence in the company.
Quiver AI Summary
Burning Rock Biotech Limited announced that its founder and CEO, Mr. Yusheng Han, has acquired 31,487 American Depository Shares (ADSs) worth US$546,603.90 from the open market, complying with relevant regulations and the company's insider trading policy. This purchase, combined with 41,246 ADSs acquired in a previous post-earnings trading window, totals 72,733 ADSs costing approximately US$1.36 million, demonstrating Mr. Han's confidence in the company's prospects. He may continue to buy additional ADSs, subject to market conditions and regulatory guidelines. Burning Rock focuses on next generation sequencing technology to enhance precision oncology, including therapy selection for cancer patients and early cancer detection.
Potential Positives
- Mr. Yusheng Han, the founder and CEO, has demonstrated significant confidence in Burning Rock by purchasing 72,733 ADSs, indicating personal investment in the company’s future.
- The purchase totals over US$1.35 million, which could positively influence investor sentiment and potentially support the company's stock price.
- Mr. Han's compliance with insider trading regulations may enhance the company's reputation for transparency and governance.
- The press release highlights the company's focus on precision oncology and advances in NGS technology, showcasing its commitment to innovation in a critical healthcare field.
Potential Negatives
- High insider purchases may raise concerns about the company's stock performance and overall market confidence among other investors.
- The press release does not provide any substantial financial updates or operational performance metrics, which may indicate underlying challenges in the company's current position.
- The reliance on a single executive's purchasing activity to demonstrate confidence in the company could suggest a lack of broader positive sentiment from other shareholders or the market.
FAQ
Who is the CEO of Burning Rock Biotech Limited?
The CEO of Burning Rock Biotech Limited is Mr. Yusheng Han, who is also the founder and chairman of the board.
How many ADSs did Mr. Yusheng Han purchase?
Mr. Yusheng Han purchased a total of 72,733 ADSs of Burning Rock Biotech Limited in two trading windows.
What is the total amount spent on the ADS purchases?
Mr. Yusheng Han spent a total of US$1,358,325.18 on the purchases of Burning Rock's ADSs.
What is the focus of Burning Rock Biotech's technology?
Burning Rock Biotech focuses on next generation sequencing (NGS) technology for precision oncology applications.
Where can I find more information about Burning Rock Biotech?
More information about Burning Rock Biotech can be found on their investor relations website at ir.brbiotech.com.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$BNR Hedge Fund Activity
We have seen 7 institutional investors add shares of $BNR stock to their portfolio, and 7 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CRCM LP added 269,851 shares (+121.8%) to their portfolio in Q4 2025, for an estimated $5,437,497
- REDWOOD WEALTH MANAGEMENT GROUP, LLC added 20,023 shares (+inf%) to their portfolio in Q4 2025, for an estimated $403,463
- MARSHALL WACE, LLP added 10,903 shares (+inf%) to their portfolio in Q4 2025, for an estimated $219,695
- MORGAN STANLEY removed 10,427 shares (-46.8%) from their portfolio in Q4 2025, for an estimated $210,104
- SKYVIEW INVESTMENT ADVISORS, LLC removed 10,000 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $201,500
- PROSPERA FINANCIAL SERVICES INC added 6,430 shares (+26.0%) to their portfolio in Q4 2025, for an estimated $129,564
- AMOVA ASSET MANAGEMENT AMERICAS, INC. removed 3,035 shares (-8.7%) from their portfolio in Q4 2025, for an estimated $61,155
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
GUANGZHOU, China, April 02, 2026 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focusing on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that its founder, chairman of the board of directors and chief executive officer, Mr. Yusheng Han, has purchased 31,487 of the Company’s ADSs for US$546,603.90 from the open market, which was conducted in compliance with the applicable rules and regulations and the Company’s insider trading policy. As of the date of this press release, combined with 41,246 ADSs purchased in the last post-earnings trading window, Mr. Han has purchased an aggregate of 72,733 of the Company’s ADSs for US$1,358,325.18 across two consecutive post-earnings trading windows, indicating his confidence in the Company’s business and prospect.
Mr. Han may continue to purchase the Company’s ADSs through open-market transactions, privately negotiated transactions or block trades, or other legally permissible means, depending on market conditions and in accordance with the applicable rules and regulations. The timing and conditions of Mr. Han’s purchase will be subject to various factors, including the requirements under Rule 10b-18 and Rule 10b5-1 of the Securities Exchange Act of 1934, as well as the Company’s insider trading policy.
About Burning Rock
Burning Rock Biotech Limited (NASDAQ: BNR), whose mission is to guard life via science, focuses on the application of next generation sequencing (NGS) technology in the field of precision oncology. Its business consists of i) NGS-based therapy selection testing for late-stage cancer patients, and ii) cancer early detection, which has moved beyond proof-of-concept R&D into the clinical validation stage.
For more information about Burning Rock, please visit: ir.brbiotech.com.
Contact: [email protected]
